Summary:
Previse’s newly published study in the American Journal of Gastroenterology validates the reliability of Esopredict, a DNA methylation-based test, in assessing Barrett’s esophagus patients’ risk of neoplastic progression, reinforcing its role in clinical decision-making.
Takeaways:
- Reliable Risk Assessment: Esopredict effectively identifies high-risk Barrett’s esophagus patients, aiding in earlier intervention while reducing unnecessary procedures.
- Consistent Performance: The study confirms Esopredict’s robustness, showing consistent results regardless of biopsy location or timing.
- Clinical Impact: Esopredict provides actionable insights to gastroenterologists, improving patient management and potentially reducing esophageal cancer cases.
Previse, a gastrointestinal health company, announced a newly published study in the American Journal of Gastroenterology, which provides additional clinical validation of Esopredict, a commercially available test that uses DNA methylation to assess the risk of future neoplastic progression in patients with precancerous Barrett’s esophagus. These findings reinforce Esopredict’s value in clinical decision-making, supporting earlier intervention for high-risk patients while reducing unnecessary procedures for those at low risk.
“Barrett’s esophagus is the only known precursor to esophageal adenocarcinoma (EAC), a highly lethal cancer with increasing incidence rates. At Previse, we are focused on rigorous research that supports better patient outcomes. This study marks a critical advancement for Esopredict in the field of Barrett’s esophagus care and management as an effective risk stratification solution,” says Daniel Lunz, chief executive officer at Previse.
Esopredict Shown to Be Robust in Obtaining Biopsy
In this publication, titled Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Barrett’s Esophagus Patients, Esopredict was performed at multiple locations and time points within each patient. For example, during one endoscopy, biopsies were obtained at different locations within the Barrett’s esophagus segment (spatial/location). Regardless of where the biopsy was obtained, Esopredict’s performance was similar. Likewise, endoscopies were performed at periodic intervals in each patient (temporal/time point). Regardless of when the biopsy was obtained, Esopredict’s performance was similar. Thus, this study establishes Esopredict’s robustness regardless of which biopsy is used from a patient’s endoscopy, both spatially and temporally.
“Gastroenterologists have expressed the need for a more precise way to identify which Barrett’s patients are truly at risk of developing esophageal cancer,” says Sarah Laun, PhD, vice president of Research and Development at Previse. “This study confirms that Esopredict provides actionable insights that can help optimize patient management and improve outcomes for patients living with Barrett’s esophagus.”
Featured Image: Yurii Kibalnik | Dreamstime.com
